NASDAQ:PBYI
Puma Biotechnology, Inc.
Puma Biotechnology, Inc.'s revenue fell 0.9% in fiscal 2025 to $228.4M while operating margin rose to 16.3%, its highest in 9 years. Free cash flow was $41.7M, 18.3% of revenue, and the diluted share count rose 3.2%.Summary generated from Puma Biotechnology, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$228.4M
Revenue growth−0.9%
Revenue, 5-yr CAGR+0.3%
Gross margin74.5%
Operating margin16.3%
Net margin13.6%
ROIC30.3%
Return on equity28.0%
Debt / equity0.17
Free cash flow$41.7M
FCF margin18.3%
Share count change+3.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 253 | 228 | 236 | 230 | 228 |
| Operating income | 1 | 24 | 33 | 31 | 37 |
| Net income | −29 | 0 | 22 | 30 | 31 |
| Free cash flow | 21 | −16 | 27 | 39 | 42 |
Recent filings
- 4Insider transaction report
Sep 16, 2026 - 4Insider transaction report
Sep 16, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KResults of a shareholder vote
Jun 16, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 7, 2026 - DEF 14AProxy statement
Apr 28, 2026